A
Acceleron Pharma
Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics
At a glance
- Founded
- 2004
- Headquarters
- Cambridge, United States
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Acceleron Pharma.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later11 investors entered at this stage
- HUHarvard University
Flagship Pioneering
OrbiMed
Polaris Partners- CECelgene
- MBMPM BioImpact
Venrock- SSSalk Institute for Biological Studies
Bessemer Venture Partners
Foresite Capital- AVAdvanced Technology Ventures
Source: Dealroom Talent Intelligence.
Alumni founders
Former Acceleron Pharma employees who went on to found companies, sorted by Dealroom signal score.
ATAN2 TherapeuticsEst. 2019
KAKallyopeEst. 2015
OVOvaScienceEst. 2011
Christoph WestphalUnited States
OBOorja BioEst. 2023
Sujay KangoUnited StatesGlobal footprint
across markets
Patents
101 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acceleron Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acceleron Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.